CSRXP: WYDEN RX PRICING PRINCIPLES ADD TO MOMENTUM IN WASHINGTON TO HOLD BIG PHARMA ACCOUNTABLE

Lawmakers Must Advance Solutions to Lower Drug Prices  For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing

06-22-2021 Read More

WHAT THEY ARE SAYING: BIOGEN’S “SIMPLY UNACCEPTABLE” ADUCANUMAB PRICING HIGHLIGHTS URGENCY FOR RX SOLUTIONS

Broad-based Opposition to Egregious Launch Price on Drug With Unproven Clinical Benefit Adds to Momentum to Hold Big Pharma Accountable Last week, the U.S. Food and Drug Administration (FDA)

06-14-2021 Read More

CSRXP: FDA APPROVAL AND SUBSEQUENT BIOGEN PRICING OF ADUCANUMAB DEMAND RETROSPECTION, REFORM

Troubling for Public Health Institution to Depart from Established Norms to Support Drug of Questionable Efficacy with Unjustifiable Price Tag For Immediate Release Contact: Jon Conradi 860-235-3884

06-11-2021 Read More

ICYMI: BIG PHARMA’S FASTER-THAN-INFLATION PRICE HIKES COSTING MEDICARE BILLIONS OF DOLLARS

AARP Study Finds Brand Name Drug Companies Increased Prices Above Rate of Inflation on 90 Percent of Best-Selling Part D Medications In case you missed it, AARP released a new report Monday

06-7-2021 Read More

SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC

For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation

06-7-2021 Read More

CSRXP AD BLITZ: LAWMAKERS MUST HOLD BIG PHARMA ACCOUNTABLE NOW

Campaign Calls for Promises Made to the American People to Lower Prescription Drug Prices to Become Promises Kept For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected]

06-1-2021 Read More

CSRXP COMMENDS PRESIDENT BIDEN FOR RENEWING COMMITMENT TO LOWERING PRESCRIPTION DRUG PRICES IN BUDGET

Time for the Administration and Congress to Convert Promises Made Into Promises Kept For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign

05-28-2021 Read More

THEY SAID IT! ABBVIE CEO BRAGS ON ABILITY TO HIKE PRICES IN U.S., ADMITS COMPETITION WORKS AND CONFIRMS BIG PHARMA PATENT GAMES DESIGNED FOR “PRICING POWER”

House Oversight Lawmakers Commit to Bipartisan Action to Hold Big Pharma Accountable During Explosive Hearing on Out-of-Control Drug Prices During a hearing Tuesday before the U.S. House Committee

05-19-2021 Read More

DOSE OF REALITY: HUMIRA: A CASE STUDY IN BIG PHARMA GREED

AbbVie CEO Headed for Capitol Hill to Answer for Indefensible Anti-Competitive  & Price-Hiking Tactics on World’s Best-Selling Drug On Tuesday, lawmakers in the U.S. House Committee on

05-17-2021 Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.